Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Gilead Triple Combination HIV Therapy Has Back-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb and Gilead are developing a "back-up" formulation of the fixed-dose combination of Sustiva and Truvada that is the subject of their joint venture

You may also be interested in...



Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says

Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.

Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says

Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.

Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo

The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel